Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 220.42 USD 4.88% Market Closed
Market Cap: 13.6B USD

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 266.29 USD with a low forecast of 222.2 USD and a high forecast of 341.25 USD.

Lowest
Price Target
222.2 USD
1% Upside
Average
Price Target
266.29 USD
21% Upside
Highest
Price Target
341.25 USD
55% Upside
Ascendis Pharma A/S Competitors:
Price Targets
688192
Dizal Jiangsu Pharmaceutical Co Ltd
56% Upside
AVCT
Avacta Group PLC
6% Upside
FHTX
Foghorn Therapeutics Inc.
169% Upside
ALEC
Alector Inc
40% Upside
COYA
Coya Therapeutics Inc
165% Upside
BSLN
Basilea Pharmaceutica AG
52% Upside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 4 years is 63%.

30%
Past Growth
63%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
266.29 USD

According to Wall Street analysts, the average 1-year price target for ASND is 266.29 USD with a low forecast of 222.2 USD and a high forecast of 341.25 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
63%

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 4 years is 63%.

Back to Top